Sarepta Therapeutics - Company & Market Research Reports

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.


Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017

  • Report
  • 79 Pages
From
Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022 - Product Thumbnail Image

Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022

  • Report
  • 100 Pages
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • 35 Pages
From
Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Muscular Dystrophy - Pipeline Review, H1 2018

  • Report
  • 152 Pages
From
Becker Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Becker Muscular Dystrophy - Pipeline Review, H1 2018

  • Report
  • 46 Pages
From
Duchenne Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H1 2018

  • Report
  • 305 Pages
From
Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026 - Product Thumbnail Image

Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026

  • Report
  • 49 Pages
From
Systemic Lupus Erythematosus - Pipeline Review, H1 2018 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Review, H1 2018

  • Report
  • 446 Pages
From
Systemic Lupus Erythematosus - Pipeline Review, H2 2017 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Review, H2 2017

  • Report
  • 427 Pages
From
Influenza A Viral Infections Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Influenza A Viral Infections Drug Development Pipeline Review, 2018

  • Report
  • 188 Pages
From
Swine and Avian Influenza Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Swine and Avian Influenza Drug Development Pipeline Review, 2017

  • Report
  • 119 Pages
From
Transplantation Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Transplantation Drug Development Pipeline Review, 2017

  • Report
  • 242 Pages
From
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018 - Product Thumbnail Image

Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018

  • Report
  • 465 Pages
From
Dystrophin (DMD) - Pipeline Review, H1 2018 - Product Thumbnail Image

Dystrophin (DMD) - Pipeline Review, H1 2018

  • Report
  • 80 Pages
From
Acinetobacter Infections - Pipeline Review, H1 2018 - Product Thumbnail Image

Acinetobacter Infections - Pipeline Review, H1 2018

  • Report
  • 154 Pages
From
Klebsiella pneumoniae Infections - Pipeline Review, H1 2018 - Product Thumbnail Image

Klebsiella pneumoniae Infections - Pipeline Review, H1 2018

  • Report
  • 110 Pages
From
Pseudomonas aeruginosa Infections - Pipeline Review, H1 2018 - Product Thumbnail Image

Pseudomonas aeruginosa Infections - Pipeline Review, H1 2018

  • Report
  • 260 Pages
From
Dengue Fever - Pipeline Review, H1 2017 - Product Thumbnail Image

Dengue Fever - Pipeline Review, H1 2017

  • Report
  • 170 Pages
From
Burkholderia Infections - Pipeline Review, H2 2016 - Product Thumbnail Image

Burkholderia Infections - Pipeline Review, H2 2016

  • Report
  • 75 Pages
From
Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016 - Product Thumbnail Image

Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016

  • Report
  • 98 Pages
From
Loading Indicator
adroll